ClinicalTrials.Veeva

Menu

To Perform a Post-market Study of the Performance of the Idylla ThyroidPrint Assay Using Clinical Samples in Predicting the Nature of Indeterminate Thyroid Nodules (ITNs) Across Multiple Centers.

R

Royal Cornwall Hospitals Trust

Status

Enrolling

Conditions

Thyroid Cancer

Study type

Observational

Funder types

Other

Identifiers

NCT06849284
2425.RCHT.12

Details and patient eligibility

About

To perform a post-market study of the performance of the Idylla™ ThyroidPrint® Assay using clinical samples in predicting the nature of indeterminate thyroid nodules (ITNs) across multiple centers.

Full description

This is a multicenter, non-interventional (observational), prospective, post-market study, matching the Idylla™ ThyroidPrint® RUO Assay result to the gold standard of surgical pathology.

The study population is defined as cases where the thyroid nodule has been reported as indeterminate.

Primary endpoints are the calculation of the sensitivity, specificity, and the negative and positive predictive values of the Idylla™ ThyroidPrint® RUO Assay for indeterminate thyroid nodules.

Secondary endpoint: to assess the failure rate of Idylla™ ThyroidPrint® RUO Assay, including errors and invalids; describe the nature of false negative and false positive cases.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Thyroid nodule ≥1.0 cm
  • With indeterminate cytology
  • Surgery due to be performed

Exclusion criteria

  • Specimens which fail to meet the inclusion criteria.
  • FNA fixed in formalin or transferred in alcohol-based collection buffers which is not according to the protocol instructions.
  • RNA extracts.
  • Patients with ultrasound evidence of malignant cervical adenopathy

Trial contacts and locations

1

Loading...

Central trial contact

Verity Teague Research Sponsorship Facilitator

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems